To identify the most critical bioactive compound in HXS for treating liver fibrosis by targeting CDKN1A, NR1I3, and TUBB1, we studied gene–drug interactions based on CTD (Comparative Toxicogenomics Database, available online: https://ctdbase.org/ (accessed on 29 January 2025)). The gene discussed is CDKN1A; the disease is Hepatic fibrosis.